Skip to content

Operating Income at other companies

AbbVie logo
AbbVieABBV
$3.99B+6.9%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
-$6.26M-12.4%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$46.09M+29.3%
Regenxbio logo
RegenxbioRGNX
-$83.36M-787%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$19.67M-187%
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s operating income?
Immix Biopharma, Inc. (IMMX) reported operating income of -$10.8M in Q1 2026.
How has Immix Biopharma, Inc.'s operating income changed year-over-year?
Immix Biopharma, Inc.'s operating income decreased by 130.7% year-over-year, from -$4.68M to -$10.8M.
What is the long-term trend for Immix Biopharma, Inc.'s operating income?
Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s operating income has grown at a 117.0% compound annual growth rate (CAGR), from -$1.35M to -$29.96M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.